GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.55 -0.48 (-1.02%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

45 46 Next >

Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion ↗

November 17, 2023

Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump.

Via Benzinga

Diversifying Your Portfolio With Plant-Based Options ↗

November 16, 2023

Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market...

Via Talk Markets

Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B ↗

November 16, 2023

Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over...

Via Benzinga

Current Analysis: GSK Plc ↗

November 16, 2023

In the pharmaceutical industry, GSK PLC ranks as one of the largest companies by total sales.

Via Talk Markets

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

Peering Into GSK's Recent Short Interest ↗

October 26, 2023

Via Benzinga

Price Over Earnings Overview: GSK ↗

October 24, 2023

Via Benzinga

Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology ↗

November 15, 2023

Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to...

Via Benzinga

Topics Intellectual Property Lawsuit

European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med ↗

November 13, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a posi

Via Benzinga

GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative

November 13, 2023

From GSK plc

Via Business Wire

6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367% ↗

November 08, 2023

Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth

Via InvestorPlace

GSK is a remedy for the winter investment blahs

November 07, 2023

Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.

Via MarketBeat

Topics Intellectual Property

3 Healthcare Stocks Getting Help From the Aging Population ↗

November 06, 2023

America's aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions.

Via InvestorPlace

3 Top Dividend Stock Picks for Steady Income and Capital Appreciation ↗

November 02, 2023

Conservative investors will benefit from these top dividend stock picks that are likely to generate significant returns.

Via InvestorPlace

Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares ↗

November 02, 2023

The company issued below-consensus sales views for 2023 and 2024.

Via Investor's Business Daily

GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch ↗

November 01, 2023

The company is rivaling Pfizer, which also gained approval this year for an RSV vaccine.

Via Investor's Business Daily

GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot ↗

November 01, 2023

GSK plc (NYSE: GSK) reported Q3 FY23 s

Via Benzinga

Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News' ↗

November 01, 2023

U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings.

Via Benzinga

Topics Economy Stocks

Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK ↗

October 31, 2023

GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have

Via Benzinga

Hope for Endometrial Cancer - GSK Drug Proves Effective in Increasing Survival Rates ↗

October 30, 2023

GSK plc (NYSE: GSK)

Via Benzinga

Earnings Scheduled For November 1, 2023 ↗

November 01, 2023

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.

Via Benzinga

GSK's Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales ↗

October 30, 2023

GSK (NYSE: GSK) has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer Inc (NYSE: PFE), which previously dominated the COVID-19...

Via Benzinga

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

October 30, 2023

Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...

From 23andMe, Inc.

Via GlobeNewswire

Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal ↗

October 28, 2023

Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its...

Via Talk Markets

3 Bill Gates Stocks to Buy for Billionaire-Like Returns ↗

October 27, 2023

Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less.

Via InvestorPlace

3 Deeply Undervalued Growth Stocks ↗

October 27, 2023

As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks.

Via InvestorPlace

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

October 27, 2023

From Alector, Inc.

Via GlobeNewswire

New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

October 25, 2023

From GSK plc

Via Business Wire

Bank Of America, Mastercard, NRA And Others Are Lobbying For Cannabis Banking Reform — Who Knew? ↗

October 22, 2023

Several entities have included the Secure and Fair Enforcement Regulation (SAFER) Banking Act on their lobbying disclosures for the third quarter of 2023.

Via Benzinga

Topics Cannabis

Week In Review: Two China Biopharmas Announce Billion Dollar Deals ↗

October 14, 2023

MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...

Via Talk Markets

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.